Recursion reported fourth-quarter revenue of $10.89 million, which missed the consensus estimate of $20.35 million. The clinical stage biotech company reported a quarterly loss of 42 cents per share, which beat estimates for a loss of 44 cents per share, according to Benzinga Pro
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 50 points on Friday. The Dow traded up 0.13% to 37,490.36 while the NASDAQ rose 0.25% to 14,546.77. The S&P 500 also rose, gaining, 0.26% to 4,701.05.